<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792139</url>
  </required_header>
  <id_info>
    <org_study_id>16616</org_study_id>
    <secondary_id>I8X-MC-JECC</secondary_id>
    <nct_id>NCT03792139</nct_id>
  </id_info>
  <brief_title>An Interaction Study of LY3200882 in Healthy Participants</brief_title>
  <official_title>Effects of CYP3A4 Inhibition by Itraconazole on the Pharmacokinetics of LY3200882 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the effect of itraconazole on the amount of
      LY3200882 in the blood stream and how long the body takes to get rid of LY3200882. The safety
      and tolerability of LY3200882 when given with itraconazole will be evaluated. The study is
      expected to last up to 19 days from the first dose to follow-up (inclusive). Screening will
      occur up to 28 days prior to enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2019</start_date>
  <completion_date type="Actual">February 23, 2019</completion_date>
  <primary_completion_date type="Actual">February 23, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3200882</measure>
    <time_frame>Baseline through 72 hours post-dose</time_frame>
    <description>PK: Cmax of LY3200882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Curve (AUC) of LY3200882</measure>
    <time_frame>Baseline through 72 hours post-dose</time_frame>
    <description>PK: AUC of LY3200882</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3200882</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3200882 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Itraconazole + LY3200882</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itraconazole + LY3200882 administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3200882</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Itraconazole + LY3200882</arm_group_label>
    <arm_group_label>LY3200882</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Itraconazole + LY3200882</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or postmenopausal females, as determined by medical history and physical
             examination

        Exclusion Criteria:

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Have used or intend to use over-the-counter or prescription medication including
             herbal medications within 14 days prior to dosing and during the study (with the
             exception of vitamins and occasional acetaminophen or ibuprofen, which will be
             permitted at the discretion of the investigator). Drugs that are known substrates,
             inducers, or inhibitors of CYP3A4 are specifically excluded within 30 days of dosing
             and throughout the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

